share_log

BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25

Benzinga ·  Apr 26 14:01

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target from $18 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment